anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a space mutagenesis strain with high yield and high efficiency, and the use of the strain. The present invention is characterized in that an alpha-hemolytic streptococcus strain is carried by a roundtrip type spacecraft, and the hereditary property of the alpha-hemolytic streptococcus strain is changed under the special space conditions; strains with positive mutation and stable hereditary property are preferably selected to be used as production strains. The space mutagenesis strain is preserved by the China General Microbiological Culture Collection Center, and the serial number is CGMCC No. 1082. The carried alpha-hemolytic streptococcus strain is No. 33 strain of the alpha-hemolytic streptococcus. In the space mutagenesis strain with high yield and high efficiency, and the use of the strain, special environment is used for changing the hereditary property of the strain, strains with positive mutation and stable hereditary property are preferably selected to be used as production strains, and the space mutagenesis strain has the advantages of high yield, wide application range and high efficiency.
The invention discloses a co-amorphous system and a preparation method thereof. The co-amorphous system comprises pioglitazone hydrochloride and glimepiride. The analysis by the powder X-ray diffraction technology confirms that the pioglitazone hydrochloride and the glimepiride exist in an amorphous form. The analysis by the differential scanning calorimetry finds that the pioglitazone hydrochloride and the glimepiride have strong intermolecular interaction. By using the co-amorphous matter, a new idea is provided for the combined medication. The co-amorphous matter is easy to smash and is convenient to preserve. The invention further provides a compound medicinal preparation containing the co-amorphous system.
YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD. YUPELRI has not been studied in subjects with acutely deteriorating COPD. The initiation of YUPELRI in this setting is not appropriate.

YUPELRI is intended as a once-daily maintenance treatment for COPD and should not be used for relief of acute symptoms, i.e. as rescue therapy for the treatment of acute episodes of bronchospasm, and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If YUPELRI no longer controls symptoms of bronchoconstriction, the patient's inhaled, short-acting beta2-agonist becomes less effective, or the patient needs more inhalations of a short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dose of YUPELRI beyond the recommended dose is not appropriate in this situation.
The invention provides a Pingyangying defensive foot heat-dispelling powder, which is added with cinnamon and folium artemisiae argyi to eliminate deficiency cold of lower jiao, warm channels and dispel heat, and supplement fire of life gate through the cinnamon to achieve the effect of warming and dredging lower jiao, and can accelerate the essence for treating cold sinking, warming and dredging primordial root and benefiting ying and defensive water fire. The technical scheme for solving the problem is that the Pingthenying and wei bubble foot heat-removing powder is characterized by comprising the following raw materials in parts by weight: 4-8 g of cinnamon, 3-5 g of argy wormwood leaf, 10-30 g of schizonepeta, 10-30 g of divaricate saposhnikovia root, 8-20 g of dahurian angelica root, 10-25 g of wrinkled gianthyssop herb, 10-15g of rhizoma atractylodis, 25-50 g of common scouring rush herb, 10-20 g of weeping forsythia and 20-30 g of white poria. The beneficial effects of the invention are: the cinnamon and folium artemisiae argyi are added to quickly cure the cold, warm and dredge the roots, and supplement nutrition and defend water and fire, so that the traditional Chinese medicine is more perfect. The addition of cinnamon and argy wormwood leaves in the invention can better dispel the syndrome of more daily damage caused by kidney cold precipitation. Deficiency-cold in the lower energizer needs to be removed through the folium artemisiae argyi and the cinnamon bark, the channel is warmed to dispel cold, and then the cinnamon bark is used for tonifying the fire of the Mingmen. So as to achieve the effect of warming and dredging the lower jiao.
Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
PURPOSE:To obtain a preventing and treating agent having high preventing and treating effects on Salmonella infectious disease and free from problem of resistance to the medicine and environmental pollution, low in toxicity to animal and hardly remaining in animal bodies and having high safety. CONSTITUTION:This preventing and treating agent for Salmonella infectious disease of animal contains at least one inactivated bacterial strain of Salmonella belonging to O4 group and at least one inactivated bacterial strain of Salmonella belonging to O9 group on classification of Salmonella by O antigen. As Salmonella belonging to O4 group, Salmonella typhimurium, Salmonella paratyphi-B, etc., and as Salmonella belonging to O9 group, Salmonella enteritidis, Salmonella dublin, Salmonella typhi are exemplified and, as the combination thereof, S. typhimurium/S. dublin and S. typhimurium/S. enteritides are preferably used and these Salmonella bacteria have especially large effects on prevention and treatment of cow Salmonella infectious diseases. When this preventing and treating agent is orally administered continuously for >=5 days, further good result is obtained.
Fibromyalgia (FM), which is a chronic pain disorder, is a difficult disease to treat, and it is stated that a multidisciplinary approach is required in its treatment rather than a single treatment method. Approaches that consider optimal symptom management and functional status in treatment, include non-pharmacological methods in addition to pharmacological treatment, and include psychosocial and behavioral methods are recommended. Non-pharmacological methods that have proven their effectiveness in FM treatment include aerobic exercise, patient education, cognitive therapies, balneotherapy, and physical therapy agents. One of the methods that can be applied in patients with FM is progressive muscle relaxation (PMR) exercises. PMR is an easy, low-cost, and side-effect-free relaxation technique. PMR helps individuals feel calmer and more relaxed through sequential muscle tension and relaxation. It has been reported in the literature that PMR is effective on pain, fatigue and stress symptoms in fibromyalgia patients. No study has been found examining the effect of PMR on kinesiophobia and functional status in FM. Therefore, this study was planned to examine the effect of progressive muscle relaxation exercises on pain, kinesiophobia and functional status in fibromyalgia patients.
Geometry has been identified as a cognitive domain where deaf individuals exhibit relative strength, yet the neural mechanisms underlying geometry processing in this population remain poorly understood. This fMRI study aimed to investigate the neural correlates of geometry processing in deaf and hearing individuals. Twenty-two adult deaf signers and 25 hearing non-signers completed a geometry decision task. We found no group differences in performance, while there were some differences in parietal activation. As expected, the posterior superior parietal lobule (SPL) was recruited for both groups. The anterior SPL was significantly more activated in the deaf group, and the inferior parietal lobule was significantly more deactivated in the hearing group. In conclusion, despite similar performance across groups, there were differences in the recruitment of parietal regions. These differences may reflect inherent differences in brain organization due to different early sensory and linguistic experiences.
The study will last for 3 months and will be limited to MECP2 mutation-positive children, one year - 9.99 years of age. This clinical trial, which is a placebo-controlled study, will randomize patients to the drug or placebo to determine the benefits of DM vs placebo on cognition, behavior, or seizures if present.

Your child will stay twice in the Pediatric Clinical Research Unit (PCRU) at Johns Hopkins ICTR, for 3 days during each admission. The first hospital stay will be for 3 days, before she starts the DM or placebo. The follow-up 3-day hospital stay will be 3 months after she starts taking DM or placebo. There will also be two interim follow up evaluations at 2 weeks and 1 month after she starts taking the DM or placebo consisting of a neurological evaluation, EKG, and blood work, which can take place at your local doctor's office or at Johns Hopkins, and will be paid for by this study. Our research nurse or research associate will contact you at least weekly during the first month, and at least monthly thereafter until the end of the 3-month study.
Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
Macrophages activation and inflammatory response play crucial roles in intracranial aneurysm (IA) formation and progression. The outcome of ruptured IA is considerably poor, and the mechanisms that trigger IA progression and rupture remain to be clarified, thereby developing effective therapy to prevent subarachnoid hemorrhage (SAH) become difficult. Recently, climbing evidences have been expanding our understanding of the macrophages relevant IA pathogenesis, such as immune cells population, inflammatory activation, intra-/inter-cellular signaling transductions and drug administration responses. Crosstalk between macrophages disorder, inflammation and cellular signaling transduction aggravates the devastating consequences of IA. Illustrating the pros and cons mechanisms of macrophages in IA progression are expected to achieve more efficient treatment interventions. In this review, we summarized the current advanced knowledge of macrophages activation, infiltration, polarization and inflammatory responses in IA occurrence and development, as well as the most relevant NF-κB, signal transducer and activator of transcription 1 (STAT1) and Toll-Like Receptor 4 (TLR4) regulatory signaling modulation. The understanding of macrophages regulatory mechanisms is important for IA patients' clinical outcomes. Gaining insight into the macrophages regulation potentially contributes to more precise IA interventions and will also greatly facilitate the development of novel medical therapy.
Participants will be given individual, standardized instructions and demonstrations for each device as per the manufacturers' instructions. The participants will practice with instructor's feedback on an infant mannequin with a normal airway until he/she feel comfortable with each of the three devices. The investigator will record the prior experience of the participant in using each of the 3 devices in clinical situations. Each subject will be asked to intubate each of the mannequins with each of the devices. The choice of the order of device and mannequin will be based on a Latin square design and the sequence will be assigned to participants based on a computer generated random number. A closed envelope technique will blind participants and investigators to the order of airway device and mannequin till the start of the individual trial. Participants will first finish the test on unchanged conditions and then repeat the process using the same order of mannequins and devices but with the neck held immobile to simulate a scenario of a child with an unstable cervical spine. Data from different scenarios will be recorded from a total number of 18 attempts of tracheal intubation per participant. Participants will be asked to proceed as though they were in the operating room with an assistant available to follow their commands. The order of presentation of each mannequin, airway device and scenario will be randomized as described above. The time from placing the device in the mannequin's mouth to the time the Ambu bag is connected to the end of the tracheal tube and a positive pressure breath is given will constitute the intubation time. During each intubation the participant will be asked to state when he or she has obtained the best view for intubation and this time this will be recorded as the time for visualization. The subject will assess the quality of the best glottic view on the Cormack - Lehane grade of 1 -4. The investigators will record all maneuvers to optimize visualization of the larynx such as tracheal pressure, lip retraction, pulling the tongue forward etc. The time from entry of the device in the mouth to the time the tracheal tube is started to be advanced is the visualization time. The time a positive pressure breath is given at the end of the tracheal tube will constitute the end of the attempt of intubation. A failed attempt is defined as removal of the laryngoscope from the mouth without a successful intubation. The number of times the endotracheal tube is advanced will also be recorded. Failure of intubation will be defined as unrecognized esophageal intubation, abandoned procedure, intubation taking longer than 120 seconds and intubation requiring more than 3 attempts. The observer will estimate the maximum force applied to the maxilla on a 0 -10 scale where 0= no force and 10 = maximum force with distortion of the maxilla. The observer will also estimate potential damage of laryngeal structures on a 0 -10 scale.
The invention discloses application of pseudolaric acid B in preparing a medicament for treating pulmonary hypertension. The invention belongs to the technical field of biological medicines. The invention constructs a pulmonary hypertension disease mouse model through hypoxia (10%) induction. After the pseudolaric acid B is injected into the abdominal cavity, the conditions of fur, diet, activity, death and the like of the pulmonary hypertension mouse model are observed. KnotThe pseudolaric acid B (shown in formula I) has the effects of remarkably improving pulmonary vascular remodeling of the pulmonary hypertension animals, relieving right ventricular hypertrophy and right heart failure, improving the living quality (improving food intake and water intake) of the pulmonary hypertension animals and improving the survival rate of the pulmonary hypertension animals. Therefore, the invention provides the pseudolaric acid B which has wide application prospect in the aspect of preventing and treating pulmonary hypertension disease.
Ovarian cancer (OC) is the female genital malignancy with the highest lethality. Patients present a poor prognosis mainly due to the late clinical presentation allied with the common acquisition of chemoresistance and a high rate of tumour recurrence. Effective screening, accurate diagnosis, and personalised multidisciplinary treatments are crucial for improving patients' survival and quality of life. This comprehensive narrative review aims to describe the current knowledge on the aetiology, prevention, diagnosis, and treatment of OC, highlighting the latest significant advancements and future directions. Traditionally, OC treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Although more therapeutical approaches have been developed, the lack of established predictive biomarkers to guide disease management has led to only marginal improvements in progression-free survival (PFS) while patients face an increasing level of toxicity. Fortunately, because of a better overall understanding of ovarian tumourigenesis and advancements in the disease's (epi)genetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients' survival. Despite this progress, several challenges in disease management, including disease heterogeneity and drug resistance, still need to be overcome.
This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone. This will be looked on on patients undergoing painful shoulder surgery in the ambulatory surgery center. Patients will be randomized to one of four groups (1. 0.75% plain ropivacaine. The reference comparator 2. A mixture of 0.75% ropivacaine with 300 mcg buprenorphine 3. A mixture of 0.75% ropivacaine with 75 mcg clonidine 4. A mixture of 0.75% ropivacaine with and 8mg dexamethasone) for their regimen in the interscalene block for their surgery. The patients will then be called within 3 days post-operatively to follow-up. Follow-up data collected will be when did the patient experience return of pain to the operative limb (duration of analgesia), when did the patient experience return of motor function of the operative limb (duration of motor block) and when did the patient experience return of sensation of the operative limb (return of sensory block). All three of these adjuvants have been studied previously and shown to have increased analgesic duration with local anesthesia, but have never had a good comparative study. The mechanism of action of the analgesia for these adjuvants pain relief has never been shown although it is likely a indirect effect as there are animal studies looking at their effect on A and C fibers that did not show those results.
Clonal hematopoiesis (CH) is an age-associated phenomenon that increases the risk of hematologic malignancy and cardiovascular disease. CH is thought to enhance disease risk through inflammation in the peripheral blood.1 Here, we profile peripheral blood gene expression in 66 968 single cells from a cohort of 17 patients with CH and 7 controls. Using a novel mitochondrial DNA barcoding approach, we were able to identify and separately compare mutant Tet methylcytosine dioxygenase 2 (TET2) and DNA methyltransferase 3A (DNMT3A) cells with nonmutant counterparts. We discovered the vast majority of mutated cells were in the myeloid compartment. Additionally, patients harboring DNMT3A and TET2 CH mutations possessed a proinflammatory profile in CD14+ monocytes through previously unrecognized pathways such as galectin and macrophage inhibitory factor. We also found that T cells from patients with CH, although mostly unmutated, had decreased expression of GTPase of the immunity associated protein genes, which are critical to T-cell development, suggesting that CH impairs T-cell function.
Coronavirus disease 2019 (COVID-19) consists mainly of a respiratory infection that spans from a mild involvement of the upper respiratory tract to severe pneumonia leading to respiratory distress, shock, and death. Fever, cough, and dyspnea/tachypnea, together with myalgia and fatigue, have been identified as the most common presenting symptoms. Most of the patients remain in a state of mild upper respiratory tract disease for a relatively long period (a median of 8-10 days), after which a proportion of up to 25% may develop severe hypoxemia and ARDS with the necessity of mechanical ventilation. Deterioration with ICU admission (most likely in older patients with comorbidities) raises the incidence of mortality in a range that goes from 3.4 up to 61%. Moreover, ICU admission poses a significant strain in terms of healthcare resources. Thus, a treatment able to avoid the progression of the disease from the mild to the severe phases would have a substantial benefit both in terms of lives saved and hospital resources spared. However, at the time, only Remdesivir and Dexamethasone have shown some benefits in robust clinical trials.

Nitric Oxide gas is a therapy currently approved for the treatment of pulmonary hypertension in newborns and is also used as rescue therapy in patients with acute respiratory distress syndrome (ARDS). The clinical role of NO gas in COVID-19 patients could be of particular relevance since there is in-vitro evidence of NO antiviral activity specifically against SARS coronavirus. At the time of the SARS pandemic, a small rescue trial on intubated patients with SARS showed that NO was effective in improving the oxygenation, fasten the resolution of chest X-ray abnormalities, and improve the clinical outcomes. Moreover, in vitro studies demonstrated that the NO-donor compound S-nitroso-N-acetylpenicillamine was able to increase the survival rate of in vitro mammalian cells infected with SARS-CoV. SARS-CoV and SARS-CoV-2 share the same subgenus inside the family Coronaviridae. The literature seems to point towards an a-specific rather than pathogen-specific antimicrobial effect of NO. Thus, the role of exogenous inhaled NO as a viricidal agent during COVID-19 infection could be hypothesized.

Nitric Oxide at high concentration has been found to be microbicidal but still safe in spontaneously breathing subjects in a phase I trial. There are several trials testing the efficacy of NO therapy in improving the outcome of COVID-19 patients. So far, only a retrospective observational study showed that NO gas is useful in improving the oxygenation in spontaneously breathing patients. However, the optimal therapeutic regimens and the efficacy of NO gas in improving the oxygenation in hypoxemic COVID-19 patients haven't been tested.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine, namely to neurosurgery, traumatology and surgery and is intended for surgical treatment of decubital wounds in case of separation of adjacent tissues in patients with consequences of spinal cord trauma. Cavity of decubital wound is densely tamponed with turunda preliminarily soaked in solution of methylene blue and 3% hydrogen peroxide with ratio of ingredients in solution 9:1. Entrance gate of decubital wound is tightly sewn with interrupted sutures. On skin, transversely to gluteal fold projection, marked is cut of ellipsoid shape sufficient for excision of bedsore capsule, with which sewn entrance gate of decubital wound are located inside excised skin section. Skin cut is performed. Pathologic focus is ablated in one block, guided by size of tamponed cavity and stained tissues. "Blind" draining of operation wound with further plasty of skin-muscular flap is performed. Antibacterial therapy is carried out for 5 days. Drainage is removed after 3 days. ^ EFFECT: method makes it possible to achieve complete and quality excision of decubital wound, reduce probability of recurrent surgery due to application of methylene blue and 3% hydrogen peroxide, extending narrow ways and slit recesses for complete staining and converting surgery from type of "purulent" into type of "clean" ones. ^ 1 ex